SCHEMBL3682274

SCHEMBL3682274

Cc1cc2ncnc(Nc3cccc(O)c3)c2cc1C

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.70
FLT1 P17948 2/20 0.70
TTBK1 Q5TCY1 2/20 0.70
RET P07949 1/20 0.70
CDK2 P24941 1/20 0.70
PIK3R1 P27986 1/20 0.70
EPHB2 P29323 1/20 0.70
KIF5B P33176 1/20 0.70
KDR P35968 1/20 0.70
NOD1 Q9Y239 1/20 0.69
GLA P06280 1/20 0.68
HTT P42858 1/20 0.68
RAF1 P04049 11/20 0.66
BRAF P15056 11/20 0.66
EGFR P00533 3/20 0.64
POLB P06746 1/20 0.60
TTBK2 Q6IQ55 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15077863 0.86 RAF1 (0.74) FGFR1FLT1TTBK1RETCDK2
SCHEMBL5569022 0.85 HTT (0.72) FGFR1FLT1TTBK1RETCDK2
SCHEMBL15077873 0.84 RAF1 (0.76) FGFR1FLT1TTBK1RETCDK2
SCHEMBL17532922 0.83 EGFR (0.72) GLAHTTRAF1EGFR
SCHEMBL15070939 0.83 EGFR (0.71) EPHB2KDREGFR
SCHEMBL30249695 0.83 KDR (1.00) FGFR1FLT1TTBK1RETCDK2
SCHEMBL29435034 0.83 KDR (1.00) FGFR1FLT1TTBK1RETCDK2
SCHEMBL1180103 0.83 KDR (1.00) FGFR1FLT1TTBK1RETCDK2
Hydrochloric Acid SCHEMBL6184184 0.82 EGFR (0.71) GLAHTTRAF1EGFR
Hydrochloric Acid SCHEMBL30433676 0.82 NOD1 (1.00) FGFR1FLT1TTBK1RETCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781423-B2 Compounds to promote regeneration of bone marrow CANCURE LABORATORIES, LLC (US) 2010-08-24 US disclosed
US-20090004136-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES LLC (US) 2009-01-01 US disclosed
WO-2008118164-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES LLC (US) 2008-10-02 WO disclosed
US-20080234234-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES, LLC (US) 2008-09-25 US disclosed
US-7423029-B1 from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts; e.g. [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride; antitumor and AIDS agent; low toxicity, side effect reduction ZOLTAN LABORATORIES, LLC (US) 2008-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090004136-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW PDGFA, BMP4, BMP2 FGFR1 947/4885FLT1 532/4885TTBK1 743/4885
US-20080234234-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW PDGFA, BMP4, BMP2 FGFR1 947/4885FLT1 532/4885TTBK1 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.